Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI-323 + Bevacizumab + Chemo in ALK+ NSCLC Post-Alectinib
NCT05296278Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI323 in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Dec 2023; status: recruiting.
02
Drugs
IBI323
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05296278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296278.